BUSINESS (Details Narrative) |
3 Months Ended | |
---|---|---|
Mar. 31, 2020 |
Jul. 28, 2016 |
|
State of Incorporation | Nevada | |
BioCorRx Pharmaceuticals, Inc [Member] | BioCorRx, Inc [Member] | ||
Description of reverse stock split | Effective January 22, 2019, the Company amended its Articles of Incorporation to implement a reverse stock split in the ratio of 1 share for every 100 shares of common stock. As a result, 259,984,655 shares of the Company’s common stock were exchanged for 2,599,847 shares of the Company’s common stock. These unaudited condensed consolidated financial statements have been retroactively restated to reflect the reverse stock split (See Note 13). | |
Officer [Member] | BioCorRx Pharmaceuticals, Inc [Member] | ||
Equity issued ownership | 75.80% | |
Noncontrolling Interest [Member] | ||
Equity issued ownership | 24.20% |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|